Mometasona Alter (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors in the cells lining the nasal mucosa. The drug‑receptor complex then alters gene transcription, decreasing the production of inflammatory cytokines and limiting vascular leakage, which together reduce nasal swelling and irritation.

The exact dosing regimen is determined by the prescribing clinician. In typical practice, one or two sprays per nostril once daily are common, but the prescriber may adjust the amount and frequency based on the patient’s age, severity of symptoms, and response to therapy.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using the product.

To order Mometasona Alter, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mometasona Alter contains mometasone furoate, a high‑potency glucocorticoid with low systemic bioavailability, offering strong local anti‑inflammatory effects. Compared with older agents such as beclomethasone or fluticasone, it often requires fewer daily sprays while delivering comparable symptom control.

Store the nasal spray at room temperature, away from direct sunlight and moisture. Keep the bottle tightly closed when not in use and protect it from extreme heat. Do not freeze the product, and discard any spray that appears discolored or contaminated.

Shake the bottle gently, remove the protective cap, and prime the spray if it is the first use. Tilt the head slightly forward, insert the nozzle into one nostril while closing the other, and press the actuator to deliver the prescribed number of sprays. Repeat in the opposite nostril as directed.

Serious risks, though uncommon, include nasal septal perforation, adrenal suppression with prolonged high‑dose use, cataracts or glaucoma, and severe allergic reactions such as anaphylaxis. Patients should report persistent nosebleeds, visual changes, or signs of systemic corticosteroid effects to their clinician promptly.

Individuals with known hypersensitivity to mometasone furoate or any component of the formulation should avoid the product. It is also contraindicated in patients with active untreated fungal, bacterial, or viral infections of the nasal passages until the infection is resolved.